货号:A372661
同义名:
甲氧沙林
/ 8-Methoxypsoralen; Xanthotoxin
Methoxsalen is a furanocoumarin and an active compound of a traditional Egyptian medicinal plant Ammi majus L, whose juice/fruit has been used for many years in folk phototherapy for the treatment of vitiligo or a hyperproliferative skin disorder, psoriasis. It is a potent suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Methoxsalen is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. Methoxsalen pretreatment prolonged the duration of nicotine-induced antinociception and hypothermia (15mg/kg, po) for periods up to 6- and 24-hr postnicotine administration, respectively[3]. Using the guinea pig as an experimental model, UV-A (long-wave UV) irradiation given immediately after the topical application of methoxsalen resulted in the notable suppression of tritiated thymidine incorporation into epidermal basal cells[4]. Oral methoxsalen when used in the higher dose followed by sun exposure is an effective treatment for psoriasis[5]. Administration of methoxsalen (50 mumol X kg-1 i.p.) increased 4-fold the hexobarbital sleeping time in rats. Methoxsalen (25-1000 microM) decreased cytochrome P-450 in vitro, in the presence of EDTA; this effect required NADPH and oxygen, was decreased by piperonyl butoxide and was increased by phenobarbital pretreatment. Similarly, administration of methoxsalen (125 mumol X kg-1 i.p.) decreased cytochrome P-450 and monooxygenase activities in vivo; the decrease in cytochrome P-450 was enhanced by phenobarbital pretreatment and was prevented by piperonyl butoxide[6]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00045305 | - | Completed | - | - | |
NCT00724061 | Lymphoma | Not Applicable | Terminated(Closed early due to... 展开 >> poor accrual.) 收起 << | - | United States, Illinois ... 展开 >> Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States, 60611-3013 收起 << |
NCT00045305 | Leukemia Myel... 展开 >>odysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms 收起 << | Phase 2 | Completed | - | United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259-5499 United States, Florida Mayo Clinic - Jacksonville Jacksonville, Florida, United States, 32224 United States, Massachusetts Tufts-NEMC Cancer Center Boston, Massachusetts, United States, 02111 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 United States, Ohio Jewish Hospital Cancer Center Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
4.63mL 0.93mL 0.46mL |
23.13mL 4.63mL 2.31mL |
46.26mL 9.25mL 4.63mL |
CAS号 | 298-81-7 |
分子式 | C12H8O4 |
分子量 | 216.19 |
SMILES Code | O=C1C=CC2=C(O1)C(OC)=C(OC=C3)C3=C2 |
MDL No. | MFCD00005009 |
别名 | 甲氧沙林 ;8-Methoxypsoralen; Xanthotoxin; Oxsorale; NCI-C55903; 8-MOP |
运输 | 蓝冰 |
InChI Key | QXKHYNVANLEOEG-UHFFFAOYSA-N |
Pubchem ID | 4114 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, room temperature |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|